A study of novel anti-cancer agents in patients with previously untreated NSCLC - MAGELLAN

Study identifier:D933IC00001

ClinicalTrials.gov identifier:NCT03819465

EudraCT identifier:2018-001748-74

CTIS identifier:N/A

Recruitment Complete

Official Title

A Phase IB, Open-Label, Multi-Center Study to Determine the Efficacy and Safety of Durvalumab and/or Novel Oncology Therapies, With or Without Chemotherapy, for First-Line Stage IV Non-Small Cell Lung Cancer (NSCLC) (MAGELLAN)

Medical condition

Metastatic Non-Small Cell Lung Cancer (NSCLC)

Phase

Phase 1

Healthy volunteers

No

Study drug

Durvalumab, Danvatirsen, Oleclumab, MEDI5752, Pemetrexed, Carboplatin, Gemcitabine, Cisplatin, Nab-paclitaxel, AZD2936

Sex

All

Actual Enrollment

175

Study type

Interventional

Age

18 Years - 130 Years

Date

Study Start Date: 27 Dec 2018
Primary Completion Date: 23 May 2023
Estimated Study Completion Date: 26 Mar 2026

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Feb 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria